Literature DB >> 20960238

Aberrant protein structure and diseases of the brain.

A T Welzel1, D M Walsh.   

Abstract

Extracellular fibrous amyloid deposits or intracellular inclusion bodies containing abnormal protein aggregates are pathological hallmarks of several neurodegenerative disorders and it has been hotly debated whether these aberrant protein structures merely occur as a consequence of disease or actually participate in a pathogenic cascade which culminates in neural dysfunction and death. Here, we review the role of aberrant protein structure in the two most common neurodegenerative disorders: Alzheimer's disease and Parkinson's disease and in two rare familial dementias, familial British dementia and familial Danish dementia. We also discuss possible mechanisms by which aberrant protein structures may mediate disease and the therapeutic opportunities this knowledge offers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960238     DOI: 10.1007/s11845-010-0606-z

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  57 in total

Review 1.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

2.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Common core structure of amyloid fibrils by synchrotron X-ray diffraction.

Authors:  M Sunde; L C Serpell; M Bartlam; P E Fraser; M B Pepys; C C Blake
Journal:  J Mol Biol       Date:  1997-10-31       Impact factor: 5.469

4.  X-ray diffraction studies on amyloid filaments.

Authors:  E D Eanes; G G Glenner
Journal:  J Histochem Cytochem       Date:  1968-11       Impact factor: 2.479

5.  Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.

Authors:  Takashi Saito; Nobuhisa Iwata; Satoshi Tsubuki; Yoshie Takaki; Jiro Takano; Shu-Ming Huang; Takahiro Suemoto; Makoto Higuchi; Takaomi C Saido
Journal:  Nat Med       Date:  2005-03-20       Impact factor: 53.440

Review 6.  Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-12       Impact factor: 91.245

7.  A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred.

Authors:  R Vidal; T Revesz; A Rostagno; E Kim; J L Holton; T Bek; M Bojsen-Møller; H Braendgaard; G Plant; J Ghiso; B Frangione
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

Review 8.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

Review 9.  The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease.

Authors:  Hozefa Amijee; David I C Scopes
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 10.  Amyloidosis.

Authors:  Mark B Pepys
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

View more
  1 in total

1.  Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Ghulam M Ashraf; Nigel H Greig; Taqi A Khan; Iftekhar Hassan; Shams Tabrez; Shazi Shakil; Ishfaq A Sheikh; Syed K Zaidi; Mohammad Akram; Nasimudeen R Jabir; Chelaprom K Firoz; Aabgeena Naeem; Ibrahim M Alhazza; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.